Mode
Text Size
Log in / Sign up
Phase 4 Completed N=312 Randomized Quadruple-blind Treatment

Smoking Cessation Study In Healthy Adolescent Smokers

Source: ClinicalTrials.gov NCT01312909 ↗
Enrolled (actual)
312
Serious AEs
1.6%
Results posted
Jun 2018
Primary outcomePrimary: 4-Week Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 12 — 20.2; 27.2; 18.0 percentage of participants — p=0.6337
◆ Published Evidence
Established
34citations · ~6 / year
High-dose and low-dose varenicline for smoking cessation in adolescents: a randomised, placebo-controlled trial.
The Lancet. Child & adolescent health · 2020 · Likely link

Summary

The study is designed to see if varenicline combined with age appropriate (adolescent) smoking cessation counseling will help teens quit smoking.

Linked Publications (2)

  • High-dose and low-dose varenicline for smoking cessation in adolescents: a randomised, placebo-controlled trial.
    The Lancet. Child & adolescent health · 2020 · 34 citations · Likely link
  • Population pharmacokinetics and exposure-response analyses of varenicline in adolescent smokers.
    CPT: pharmacometrics & systems pharmacology · 2021 · 1 citation · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
4-Week Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 12
20.2; 27.2; 18.0 0.6337
SECONDARY
Percentage of Participants With 7-Day Point Prevalence of Smoking Abstinence at Weeks 12, 24 and 52
31.2; 37.9; 23.0; 31.2; 35.9; 23.0 0.5793
SECONDARY
Daily Number of Cigarettes Smoked at Baseline
10.68; 9.56; 9.57
SECONDARY
Change From Baseline in Daily Number of Cigarettes Smoked at Weeks 12, 24, and 52
-8.56; -8.20; -8.01; -6.93; -7.31; -6.59 0.3540
SECONDARY
Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 24 and Week 52
10.1; 24.3; 13.0; 8.3; 20.4; 9.0 0.6133

Eligibility Criteria

Inclusion Criteria

  • Healthy male and female subjects between the ages of 12 and 19, inclusive.
  • Subjects smoking at least an average of 5 cigarettes per day, motivated to stop smoking,
  • Subjects must have at least one prior failed attempt to quit smoking.

Exclusion Criteria

  • Subjects with history, current diagnosis, or treatment of major depression disorder, anxiety disorders, panic disorder, hostility or aggression disorder, perceptual/thinking disturbances, mania, psychosis, bipolar disorder, personality disorder, eating disorder or severe emotional problems (in the past year).
  • Subjects with a prior suicide attempt: subjects hospitalized within the past 12 months due to suicidal ideation or suicidal behavior; subjects considered to have serious suicidal ideation or suicidal behavior in the past 12 months; active suicidal ideation or behavior identified at the screening or baseline visit.
  • Evidence of alcohol and substance abuse/dependence (other than nicotine) within 3 months prior to screening.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01312909) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search